Paratek Pharmaceuticals's EBIT per Share for the
three
months ended in Jun. 2023 was $-0.16.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.78.
During the past 3 years, the average EBIT per Share Growth Rate was 36.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 26.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Paratek Pharmaceuticals's EBIT per Share or its related term are showing as below:
PRTK'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -71.6 Med: 20.65 Max: 81.7
Current: 36.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Paratek Pharmaceuticals was 81.70% per year. The lowest was -71.60% per year. And the median was 20.65% per year.
PRTK's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.45
vs PRTK: 36.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals (NAS:PRTK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Paratek Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTK has been successfully added to your 